Aurobindo Pharma has received approval from the US Federal Trade Commission for its acquisition of Lannett Company. The deal is expected to close by June 2026.

Aurobindo Pharma Secures US FTC Approval for Lannett Deal

US Federal Trade Commission greenlights Aurobindo Pharma's acquisition of Lannett.
Transaction expected to close by June 2026.

Reader Takeaway: Regulatory approval secured; acquisition to boost US operations.

What just happened

Aurobindo Pharma Limited announced it has received approval from the US Federal Commerce Commission (FTC) for its planned acquisition of Lannett Company LLC. This follows an earlier announcement on July 30, 2025, where Aurobindo entered into an agreement to acquire 100% of Lannett.

Why this matters

The FTC approval removes a significant regulatory obstacle, paving the way for the completion of the acquisition. This is a key step in Aurobindo's strategy to expand its presence in the US market through inorganic growth.

The backstory

The acquisition is being conducted via Aurobindo Pharma USA Inc., a wholly-owned subsidiary. This move is part of Aurobindo's broader strategy for inorganic growth, aimed at strengthening its position in key markets like the United States.

What changes now

With regulatory approval in hand, Aurobindo Pharma can now proceed towards finalizing the transaction. The company has indicated that the deal is expected to be completed by the end of June 2026.

Risks to watch

While FTC approval is a major hurdle cleared, the primary remaining risk is the finalization of the deal within the projected timeline of June 2026. Any unforeseen delays in closing could impact the transaction.

Peer comparison

While specific peer acquisitions aren't detailed in this filing, the pharmaceutical sector frequently sees consolidation. Aurobindo's acquisition of Lannett is a significant move within this context.

Context metrics

• Agreement Date: July 30, 2025
• Anticipated Closing Date: By end of June 2026
• Acquiring Entity: Aurobindo Pharma USA Inc.
• Target: Lannett Company LLC

What to track next

Investors should monitor for official announcements regarding the final closing of the Lannett acquisition and any further strategic integration plans announced by Aurobindo Pharma.